inotuzumab ozogamicin


Also found in: Wikipedia.

inotuzumab ozogamicin

A humanised CD22 linked to calicheamicin, which is being studied as a possible therapy for acute lymphoblastic leukaemia. Early data suggests that it can induce the desirable apoptosis of malignant cells at lower doses than those required for the CD33 immunotoxin gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia,
References in periodicals archive ?
today announced that investigational antibody-drug conjugate (ADC) inotuzumab ozogamicin received Breakthrough Therapy designation from the U.
Inotuzumab Ozogamicin / CMC-544 Sales Forecast: Long Term, 2018-2024 5.
In addition, three drugs, namely, Graspa (ERYtech Pharma), Marqibo (Talon Therapeutics), and Inotuzumab Ozogamicin (Pfizer, Inc.
Data to be presented on BOSULIF[R] (bosutinib) and Investigational Antibody Drug Conjugate, Inotuzumab Ozogamicin
At present, only one drug, Inotuzumab Ozogamicin is in late stage clinical trial.
Data will also be presented featuring inotuzumab ozogamicin, an antibody-drug conjugate (ADC) that is one of several investigational therapies in Pfizer's ADC portfolio.
8 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Short-Midterm Forecast: 2015-2018 (Base Scenario) Figure 4.
hematological oncologists would prescribe Pfizer's inotuzumab ozogamicin to 40 percent of their patients with relapsed/refractory diffuse large B-cell lymphoma.
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy (Study 2005) (Poster, Abstract #2718, December 11)2
However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.
In addition, Pfizer has therapeutic targets in hematology with compounds in Phase 3 development, such as bosutinib, for the treatment of chronic myelogenous leukemia (CML), in addition to compounds in earlier development, such as inotuzumab ozogamicin for the treatment of Non-Hodgkin's Lymphoma.
9 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)